Triplet Therapy in Metastatic Clear Cell Renal Cell Carcinoma: Time to Abandon Empiric, Biomarker-unselected Intensification?

IF 8.5 1区医学 Q1 ONCOLOGY

European urology oncology Pub Date : 2026-09-21 DOI:10.1016/j.euo.2026.09.004

Javier Molina-Cerrillo, Victoria Gómez Dos Santos, Teresa Alonso-Gordoa

引用次数: 0

Abstract

Adding a third drug to standard immunotherapy combinations can prolong disease control but has not yet improved survival benefit and, when used empirically, increases toxicity. The priority now is validated biomarkers for patient selection and mechanistically distinct therapies, rather than more unselected triplets.

查看原文本刊更多论文

转移性透明细胞肾细胞癌的三联疗法：是时候放弃经验性的、未选择生物标志物的强化治疗了？

在标准免疫治疗组合中添加第三种药物可以延长疾病控制，但尚未提高生存效益，并且在经验上使用时，会增加毒性。现在优先考虑的是经过验证的生物标志物，用于患者选择和机械上独特的治疗，而不是更多未经选择的三胞胎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology oncology Multiple-

CiteScore

15.50

自引率

2.40%

发文量

128

审稿时长

20 days

期刊介绍： Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format